The monitoring process
1 / 20

The monitoring process - PowerPoint PPT Presentation

  • Updated On :

The monitoring process . Stages of a monitoring visit. Before the visit During the visit After the visit. During the visit. The monitor will assess or discuss: Site, staffing, research labs or other facilities Regulatory file and study records

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'The monitoring process' - dirk

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Stages of a monitoring visit l.jpg
Stages of a monitoring visit

Before the visit

During the visit

After the visit

During the visit l.jpg
During the visit

  • The monitor will assess or discuss:

    • Site, staffing, research labs or other facilities

    • Regulatory file and study records

    • Clinical procedures if possible or appropriate

    • Any problems and issues identified

    • Debrief at end of visit

After the visit l.jpg
After the visit

  • The monitor will

    • Complete site visit report

    • Submit the report to the sponsor

  • The sponsor will:

    • Distribute site visit report to the site

  • 4 types of monitoring visits l.jpg
    4 types of monitoring visits:

    Site assessment(pre trial)

    Site initiation

    Routine(interim) visits)

    Close out visit

    Pre study visit l.jpg
    Pre study visit

    Purpose :

    • It’s a face to face meeting with the investigator to explore the overall feasibility of the site and the investigator to participate into the study.

      May be combined with the study initiation visit.

    Study initiation visit l.jpg
    Study initiation visit


    - to uniformly provide study specific information to investigator(s) and study staff prior to study start up.

    - reassess resources and capability to conduct a research study.

    Study initiation cont l.jpg
    Study initiation(cont)

    • The monitor will meet with the study staff to discuss research obligations under GCP:

      • Investigator administrative responsibilities

      • IRB approvals and communications

      • Regulatory file requirements(ICH GCP E6 8.2)

      • Informed consent forms and process

      • Protocol and protocol amendments

      • Source documentation

      • Study product handling and accountability

      • Safety reporting

      • Protocol specific training

      • Archiving of study documents

    Study initiation cont10 l.jpg
    Study initiation (cont)

    • The monitor will

      • Review sponsor policies , standards and procedures for the conduct of clinical trials.

      • Reassess the site facilities

      • Provide additional guidance to the site as determined by his/her findings.

        The better the site initiation, the better the site


    Interim monitoring visits l.jpg
    Interim monitoring visits


    • Protection of human subjects rights and wellbeing.

    • Accuracy, completeness and verification of reported trial data.

    • Trial conduct in compliance with protocol/amendments, GCP and regulatory requirements.

    Interim visit cont l.jpg
    Interim visit (cont)

    • Review /assess the following:

      • Enrollment status, rate and any drop outs.

      • regulatory files

      • CRF’s, source documents, informed consents, AEs/SAEs/SUSARs

      • Study product

      • Protocol and regulatory compliance

      • laboratory review

      • clinical operations

  • Follow up on previously identified issues

  • Debrief

  • Source data verification process l.jpg
    Source data verification process

    Source data:

    • all information in original records and certified copies of original records of clinical findings, observations or other activities in a clinical trial necessary for the reconstruction an evaluation of the trial. (ICH GCP1.51)

      Source documents:

    • original documents, data and records(e.g. hospital records, lab notes, clinical charts, subjects diaries, pharmacy dispensing records, x-rays, subject files etc) (ICH GCP 1.52)

    Sdv process cont l.jpg
    SDV process(cont)

    • SDV: evaluation of the conformity of the data presented in CRFs with source data.

      • Main aim: confirm that the data collected is complete, accurate, reliable and verifiable so as to give confidence to sponsor and regulatory authorities in the data being used to support a marketing application.

      • Without SDV, no scientist can have confidence in data presented and conclusions derived.

    Sdv process cont15 l.jpg
    SDV process (cont)

    Key data :

    • 10 efficacy data

    • Inclusion/exclusion criteria

    • Medical/medication history

    • Physical exam/vital signs

    • visit dates

    • Adverse events

    • Concomitant medication

    • Record that patient entered clinical study and date of IC

      Any gross errors in these might be detrimental to the scientific and ethical quality of the clinical trial.

    Sdv process cont16 l.jpg
    SDV process(cont)

    • Methods of SDV:

      • Back to back

      • Direct method- monitor has direct access to source data (ICH GCP E6 1.21,5.15)

    • Extent of SDV ???

      • Depends on: clinical trial phase, quantity of data, time availability, man power availability, investigator research experience, company policy,

    Sdv process cont17 l.jpg
    SDV process (cont)

    • Common approach:

      • Critical data: focal to aims and objectives of study and must be correct.

        • Informed consent to participate

        • Clinical notes

        • Conformance to inclusion/exclusion criteria

        • Primary efficacy endpoints

        • Secondary efficacy endpoints

        • Recording and reporting of SAEs

        • Documentation that that study drug was prescribed and at the specified dosage

        • Visit dates as per protocol

      • Non-critical data e.g. very neat, high numbers of overwriting, rapid recruitment, lack of SAEs when they would be expected etc.

    Sdv process cont18 l.jpg
    SDV process(cont)

    • CRF content review:

      • Missing, incomplete or illegible entries, signatures or dates

      • Data recorded in wrong fields

      • Illogical, inconsistent or ambiguous data

      • Data omissions

      • Entries demonstrating failure to follow protocol

      • Inaccurate calculations

      • Inadequate documentation of corrections

    Sdv process cont19 l.jpg
    SDV process(cont)

    • Common problems

      • Data entered directly to CRF

      • Brief medical history/ scanty clinical notes

      • Several volumes of SD

      • SD/CRF mismatch

      • Illegible handwriting

      • Maximum acceptable error rate

  • Document the SDV process

    • SD examined

    • CRFs checked and why they were selected

    • Critical and non-critical data items checked

    • Nature and frequency of errors

    • Any corrective actions undertaken

  • Informed consent documents l.jpg
    Informed consent documents

    • What to check:

      • Each participant has personally signed and dated ICD prior to study procedures.

      • Appropriate use of independent witness

      • Correct version being used

      • Names of subjects/person giving consent, date and time

      • Investigator appropriately signed ICD and dated.

      • All pages of ICD present